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Background: Testosterone deficiency has been re-
ported in patients with Parkinson disease (PD), Alzhei-
mer disease, and Huntington disease. It is not known
whether testosterone therapy (TT) in men with border-
line hypogonadism and neurodegenerative diseases will
be of substantial benefit. Previously, we reported that tes-
tosterone deficiency ismore common in patients with PD
comparedwith age-matched control subjects, andwe also
reported in 2 small open-label studies that some non-
motor symptoms responded favorably to TT.
Objective: To define the effects of TT on nonmotor and
motor symptoms in men with PD and probable testos-
terone deficiency.
Design: Double-masked, placebo-controlled, parallel-
group, single-center trial.
Patients: Two experimental groups: patients with PD
who were receiving either TT or placebo.
Interventions: Participants received either the study
drug by intramuscular injection (200 mg/mL of testos-
terone enanthate every 2 weeks for 8 weeks) or placebo
(isotonic sodium chloride solution injections). In pa-
tients in each group, the testosterone serum concentra-
tion was obtained at each study visit. During 2 study vis-
its, testosterone levels were blindly evaluated and the
intramuscular testosterone dose was increased by 200
mg/mL if the free testosterone value failed to double from
the baseline value.
MainOutcomeMeasures: The primary outcome vari-
able was the St Louis Testosterone Deficiency Question-
naire, and secondary outcome measures included mea-
sures of mood, cognition, fatigue, motor function, and
frequency of adverse events. At the end of the double-
blind phase, all patients were offered open-label TT and
were followed up after 3 and 6 months.
Results:Fifteen patients in the placebo group (mean age,
69.9 years), receiving a mean total levodopa equivalent
dose of 924 mg/d, had a baseline free testosterone level
of 47.91 pg/mL, compared with 15 patients in the TT
group (mean age, 66.7 years), receiving an average total
levodopa equivalent dose of 734 mg/d, who had a base-
line free testosterone level of 63.49 pg/mL. Testosterone
was generallywell tolerated.More subjects in theTTgroup
experienced lower extremity edema (40% vs 20%). In 2
patients, 1 in each group, prostate-specific antigen lev-
els were elevated from baseline. The improvement in the
TT group compared with the placebo group (1.7 vs 1.1)
on the St Louis TestosteroneDeficiency Scale was not sta-
tistically significant. In addition, there were no signifi-
cant differences in motor and nonmotor features of PD
between the 2 groups, although a few subscales showed
improvements (Hopkins Verbal Learning Test, P!.04;
and Backward Visual Span subtrial, P!.03). However,
long-term open-label TT resulted in delayed but sus-
tained improvement in subjects in the TT groupwho con-
tinued to receive treatment (n=6) compared with sub-
jects in the placebo group who elected not to receive TT
(n=3).
Conclusions: Testosterone therapy was generally well
tolerated in elderly men with PD and probable testoster-
one deficiency. While there was no significant differ-
ence in the motor and nonmotor scales between the TT
and placebo groups at the end of 8 weeks compared with
baseline, this may be due to several study limitations, in-
cluding small sample size, a strong placebo effect with
intramuscular therapy, and short follow-up that did not
allowmeasurement of delayed effects of TT in some sub-
jects. Until more definitive studies are reported, practi-
tioners should be particularly cautious in treatment of
low testosterone concentrations inmenwith PD and bor-
derline testosterone deficiency, and careful consider-
ation should be given to the risks vs the benefits of TT.
Arch Neurol. 2006;63:729-735
T ESTOSTERONE DEFICIENCYmay be important inpatients with Parkinsondisease (PD),1 Alzheimerdisease, and Huntington
disease.2-5 It isnotknown,however,whether




motor symptoms (eg, bradykinesia, rigid-
ity, tremor, andgait or balancedifficulties)




be treatedwith a variety of pharmacologic
strategies.6 The nonmotormanifestations
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have beenmore therapeutically challenging.7 Previously,
we reported that testosterone deficiency was more com-
mon inpatientswithPDcomparedwithage-matchedcon-
trol subjects.3Wealso reported in2 small open-label stud-
ies that some nonmotor symptoms respond favorably to
testosterone therapy (TT).8We endeavored in this study
(theTestosteroneTherapy inPDTrial [TEST-PD]) tocon-
ductadouble-masked,placebo-controlled,parallel-group,
single-center trial to define the effects of TT on nonmo-
tor and motor symptoms in men with PD and probable
testosterone deficiency.
METHODS
Patients for the study were recruited from the University of
Florida Movement Disorders Center, Gainesville. All patients
signed an institutional review board–approved informed con-
sent form before participation. Inclusion criteria were age older
than 45 years, male sex, diagnosis of idiopathic PD by a move-
ment disorders specialist using published criteria, and free tes-
tosterone level less than 100 pg/mL (borderline testosterone
deficiency range). Criteria for exclusion included prostate-
specific antigen level greater than 4.0 ng/mL; history of pros-
tate cancer; abnormal findings at digital rectal examination; he-
matocrit higher than 49% (elevated); liver enzyme (alanine
aminotransferase and aspartate aminotransferase) levels more
than 2 times the upper limit of normal; abnormal thyrotropin,
prolactin, or morning cortisol levels; Mini-Mental State Ex-
amination score less than 26; poorly controlled diabetes melli-
tus (glycosylated hemoglobin level"7.5 or taking insulin); sleep
apnea; congestive heart failure; and any neurologic or neuro-
muscular disorder other than PD.
Subjectsweredivided into2experimental groups:patientswith
PDwhowere receivingTT(n=15) andpatientswithPDwhowere
receiving placebo (n=15). Subjects received either the study drug
by intramuscular injection (200 mg/mL of testosterone enan-
thate every 2 weeks for 8 weeks) or placebo (saline injections),
administered by a nurse whowas not involved in data collection
for the study. A summary of the study visits for both theTTgroup
and the placebo group is shown in Figure 1. Serum testoster-
one concentrationswereobtained inpatients in eachgroupat each
study visit (before 10AM). During 2 study visits, testosterone lev-
elswereblindly evaluated and the intramuscular testosteronedose
was increased by 200 mg/mL if the free testosterone level, mea-
sured at the baseline visit, failed to double (doubling of the level
was chosen to ensure that clinically relevant changes in testos-
terone occurred in the treatment group). Testosterone levels at
each study visit were measured twice, 30 minutes apart, and the
average of the 2 values was used tomake study-related decisions
about dosage increases.
Each subject participated in the study for 8weeks. At the base-
line visit, all blood samples were drawn, including blood for de-
termination of testosterone level. Screening questionnaires were
completed.The remainderof thedouble-blindportionof the study
was divided into 5 study visits at 2-week intervals. Testosterone
was administered at the end of each study visit (visits 1-4). To
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Figure 1. Flowchart shows study visits.
Table 1. Characteristics of Study Participants*
Variable Placebo Group TT Group P Value†
Age, y 69.9 ± 9.41 66.7 ± 10.26 .38
Hoehn and Yahr Parkinson stage 2.5 2.5 .99
Levodopa equivalent dose, mg/d 924.41 ± 524.36 734.43 ± 382.55 .27
Free testosterone level, pg/mL
Pretreatment 47.91 ± 20.48 63.49 ± 17.44 .03
Posttreatment 53.06 ± 26.69 333.72 ± 389.08 .009
Total testosterone level, ng/dL
Pretreatment 273.14 ± 133.00 375.50 ± 104.55 .03
Posttreatment 333.04 ± 161.11 1029.92 ± 413.49 .000
St Louis Testosterone Deficiency Questionnaire score 7.00 ± 1.51 7.73 ± 1.44 .19
Geriatric Depression Scale score 9.47 ± 7.70 11.0 ± 6.03 .55
UPDRS off score‡ 26.71 ± 9.94 26.87 ± 9.43 .97
Abbreviations: TT, testosterone therapy; UPDRS, Unified Parkinson Disease Rating Scale.
SI conversion factor: To convert total testosterone to nanomoles per liter, multiply by 0.0347.
*Data are given as mean ± SD unless otherwise indicated.
†Based on 2-sample t tests between the 2 groups.
‡UPDRS off indicates at least 12 hours without any Parkinson disease medications.
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tional well-being, the following questionnaires were adminis-
tered serially at various times: the St Louis Testosterone Defi-
ciency Questionnaire9 (primary outcome measure), the
Massachusetts Male Aging Study Questionnaire,10 the Multidi-
mensional Fatigue Inventory,11 the Sickness Impact Profile,12 and
the Parkinson’s DiseaseQuestionnaire (PDQ-39).13 To assess be-
havioral features, the Geriatric Depression Scale (GDS),14,15 the
State-TraitAnxiety Inventory,15 and theVisualAnalogMoodScale16
were administered. To assessmotor function, all subjects under-
went a videotaped Unified Parkinson’s Disease Rating Scale
(UPDRS)17 evaluation (UPDRS off, ie, at least 12 hours without
any PDmedications, andUPDRS on, ie, 1 hour after taking usual
PD medications) with blind ratings by a neurologist trained in
movement disorders. To track cognitive status, a comprehen-
sive neuropsychologic battery of tests18 was administered, includ-
ing the Mini-Mental State Examination19; controlled oral word
association task18,20; block design subtest of the Wechsler Adult
Intelligence Scale;Mental RotationsTest; digit span subtest of the
Wechsler Memory Scale; visual span subtest of the Wechsler
Memory Scale (3rd ed)21-24; and the Subject Ordered Pointing
Task,25-27 Trail Making Test,18,28 Stroop task test,29 and Hopkins
Verbal Learning Test.30 Each test administered was analyzed us-
ingmeans (SDs) for each group. Simple repeated analysis of vari-
ancemeasureswere calculated, with the testing time (before and
after studydrug)used as thewithin-subjects variable and the treat-
ment group (testosteronevsplacebo) as thebetween-subjects vari-
able. Following the blinded portion of the study, all patientswere




A summary of patient characteristics is given in Table 1.
There were no significant differences between the TT and
control groups except that, although both groups were
testosterone deficient, the placebo group had lower base-
line levels.
SAFETY
A summary of adverse events comparing the TT vs the
control group is given in Table 2. The most frequent
adverse event was a change or worsening of motor symp-
toms of PD, but there was no statistically significant dif-
ference between the TT and placebo groups (23.3% vs
26.7%). Testosterone was generally well tolerated. More
subjects in theTTgroup comparedwith the placebo group
had lower extremity edema (40% vs 20%). Other no-
table adverse effects between groups included epistaxis
(13% vs 0%), falling (20% vs 7%), increased libido (20%
vs 7%), and increased dyskinesia (13% vs 0%). In 2 pa-
tients, 1 in each group, prostate-specific antigen levels
were elevated from baseline beyond the 4.0 ng/mL re-
quired for study enrollment; elevated absolute levels were
4.6 ng/mL in the patient in the TT group and 5.5 ng/mL
in the patient in the placebo group.
PRETREATMENT VS POSTTREATMENT DATA
IN THE STUDY AND PLACEBO GROUPS
A summary of pretreatment data vs posttreatment data
in both the TT and placebo groups is given in Table 3.
TESTOSTERONE SERUM CONCENTRATIONS
Study subjects enrolled in the TT arm had a significant in-
crease in testosterone levels from baseline to final visit
(P!.02). A dosage increase was required in 15 patients in
the TT group at visit 3 and in 4 patients at visit 4. The dos-
agewas adjusted to ensure aminimumdoubling of the free
testosterone level in all subjects assigned to the TT group.
Table 2. Adverse Events in the Testosterone Therapy (TT)






Worsening of dyskinesias* 2 (6.7) 0
Increase in PSA† 1 (3.3) 1 (3.3)
Change or worsening of PD 7 (23.3) 8 (26.7)
Edema 6 (20) 3 (10)
Worsening of gait 5 (16.7) 5 (16.7)
Fatigue 3 (10) 3 (10)
Increased libido 3 (10) 1 (3.3)
Sleep disturbance 2 (6.7) 2 (6.7)
Bleeding 2 (6.7) 1 (3.3)
Change in behavior 2 (6.7) 1 (3.3)
Coryza 2 (6.7) 0
Increased perspiration 2 (6.7) 0
Numbness 2 (6.7) 0
Pain 1 (3.3) 3 (10)
Cramps 1 (3.3) 2 (6.7)
Flulike symptoms 1 (3.3) 1 (3.3)
Constipation 1 (3.3) 1 (3.3)
Visual changes 1 (3.3) 1 (3.3)
Hypertension 1 (3.3) 1 (3.3)
Increased salivation 1 (3.3) 1 (3.3)
Restless leg syndrome 1 (3.3) 1 (3.3)
Nausea 1 (3.3) 1 (3.3)
Angular cheilitis (recurrence) 1 (3.3) 0
Asthenia 1 (3.3) 0
Chipped tooth 1 (3.3) 0
Dizziness 1 (3.3) 0
Hallucination 1 (3.3) 0
Increased sensitivity to temperature 1 (3.3) 0
“Medicine” taste in mouth 1 (3.3) 0
Vivid dreaming 1 (3.3) 0
Arthralgia 0 3 (10)
Headache 0 3 (10)
Rash 0 3 (10)
GI tract disturbance 0 2 (6.7)
Worsening of cognition 0 2 (6.7)
Dry mouth 0 2 (6.7)
Arrhythmia 0 1 (3.3)
Diarrhea 0 1 (3.3)
Dysphagia 0 1 (3.3)
Difficulty with speech 0 1 (3.3)
Drowsiness 0 1 (3.3)
Dry eyes 0 1 (3.3)
Cough 0 1 (3.3)
Shortness of breath 0 1 (3.3)
Hirsutism 0 1 (3.3)
Abbreviations: GI, gastrointestinal; PD, Parkinson disease;
PSA, prostate-specific antigen.
*Dyskinesias were rated moderate to severe and required change in
PD medication regimen.
†Asymptomatic elevation in PSA level resulted in referral to a urologist for
full evaluation.
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TESTOSTERONE DEFICIENCY SCALES
The study was powered to determine a 25% difference
between the scores on the St Louis Testosterone Defi-
ciency Scale before and after treatment between the TT
and placebo groups. No significant change was detected
between the groups. There was a significant improve-
ment in question 5 (P!.007) (Have you noticed de-
creased enjoyment in your life?) and question 9 (P!.04)
(Have you noted a recent deterioration in your ability to
play sports?) in the TT group compared with the pla-
cebo group. There were no significant changes before or
after treatment in the Massachusetts Male Aging Study
Questionnaire.
QUALITY OF LIFE AND FATIGUE SCALES
No significant changes on the PDQ-39 were noted in
the TT group. The placebo group demonstrated
improvement in the mobility subscale of the PDQ-39
(P!.02). The TT group exhibited worsening in both
the Sickness Impact Profile sleep and home functioning
subsections, whereas the placebo group showed
improvements in the same 2 subscales (P!.006 and
P!.02, respectively). No significant changes were seen
in the subscales of the Multidimensional Fatigue
Inventory.
MOOD AND COGNITIVE TESTING
No significant changes were noted in any mood scales
(Geriatric Depression Scale, State-Trait Anxiety Inven-
tory, and Visual AnalogMood Scale). Scores on the Hop-
kins Verbal Learning Test initial encoding trial 1 were
significantly improved in the TT group compared with
the placebo group (P!.03), as was the backward visual
span (Corsi blocks) (P!.03). No significant changeswere
found in any of the remaining cognitive scales (Con-
trolled Oral Word Association task; block design sub-
test of theWechsler Adult Intelligence Scale; Mental Ro-
tations Test; digit span subtest of the Wechsler Memory
Scale; visual span subtest of theWechsler Memory Scale
[3rd ed]; and Subject Ordered Pointing Task, Trail Mak-
ing Test, and Stroop test).
MOTOR TESTING
No significant changes were seen in the UPDRS testing
(blinded video review of on-off evaluations before and
after treatment).
OTHER ANALYSES
Repeated-measures analyses of variances and linear re-
gression analyses were performed on all scales adminis-
tered at each of the 5 study visits, and no significant
changes were identified. A subanalysis (repeat analysis
of the entire study data set) was also performed in pa-
tients in both groups with the lowest baseline testoster-
one levels (!330 ng/dL [!11.4 nmol/L]), and no sig-
nificant changes were found (this subanalysis was
underpowered because of small sample size).
OPEN-LABEL FOLLOW-UP
Subjects in the TT group in the open-label phase of the
study who elected to continue TT (n=6) showed a de-
layed, but sustained, improvement in the St Louis Tes-
tosterone Deficiency Scale at the end of 3 and 6 months
compared with subjects in the placebo group who chose
not to receive TT (n=3) (Figure 2). In addition, analy-
sis of the subjects whowere originally randomized to the
placebo groupwho later chose to receive TT in the open-
label phase (n=3) showed further improvement in the
St Louis Testosterone Deficiency Scale at 3- and 6-month
follow-up visits (Figure 3).
COMMENT
Testosterone therapy was administered safely and was
generally well tolerated by the elderly male subjects with
PD in this study. There was no sustained elevation of
prostate-specific antigen levels, prostate cancer, or seri-
Table 3. Results of Baseline Measurements Compared With Posttreatment Measurements*†
Examination/Test
Control Group TT Group
P
Value‡Pretreatment Posttreatment Pretreatment Posttreatment
St Louis Testosterone Deficiency Scale, total score 7.00 ± 1.51 5.87 ± 2.95 7.62 ± 1.50 5.92 ± 2.29 .56
PDQ-36, mobility score 36.33 ± 30.06 27.50 ± 28.32 32.68 ± 25.52 33.93 ± 27.17 .02
SIP, sleep score 29.12 ± 21.31 20.07 ± 17.42 23.86 ± 25.68 33.77 ± 21.77 .006
SIP, home score 22.16 ± 22.22 14.16 ± 13.90 25.07 ± 21.58 32.80 ± 29.95 .08
HVLT score −0.998 ± 1.10 −1.22 ± 0.66 −0.51 ± 1.11 −0.05 ± 0.85 .04
Backward Visual Span subtest score 54.53 ± 28.98 38.93 ± 27.92 50.00 ± 28.53 57.07 ± 20.51 .03
Abbreviations: HVLT, Hopkins Verbal Learning Test; PDQ-36, Parkinson’s Disease Questionnaire; SIP, Sickness Impact Profile; TT, testosterone therapy.
*Table gives the results of the primary outcome variable, the St Louis Testosterone Deficiency Scale score, and the results of any subscale that showed a
significant change. These included the scores for the following: PDQ-39 subscale for mobility, the SIP subscales for sleep and home functioning, the HVLT, and
the Backward Visual Span subtest. Simple repeated analysis of variance measurements were calculated with the testing time (before study drug and after study
drug) used as the within-subjects variable and TT group (TT group vs placebo group) as the between-subjects variable.
†Data are given as mean ± SD.
‡Based on 2-sample t tests (based on the difference between the TT and placebo groups for improvements that were defined as the arithmetic difference of
pretreatment and posttreatment data).
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ous adverse events in either the TT or the placebo
group.
The results of this study reveal an improvement in the
TTgroupcomparedwith theplacebogroup(1.7vs1.1)on
theStLouisTestosteroneDeficiencyScale;however, itwas
not statistically significant. There were no significant dif-
ferences inmotorandnonmotor featuresofPDinmenwith
possible testosteronedeficiencywhoreceivedTT.Because
largenumbersof statistical testswere conducted in a small
sample, the fewsignificantdifferences thatwere foundbe-
tweengroupswere likely chance findings, especially since
there was no clear direction of effects. There is a possibil-
ity that, given a larger number of study subjects, quality-
of-lifemeasures suchas those for sleepandhomefunction-
ing may worsen with TT, and this will require a better-
powered study. These results raise an important question
as to why testosterone levels in patients with PD who are
possibly testosterone deficient fail to improve with TT,
whereas similar groupsof elderlypatients seemtodemon-
strateimprovement.31-33Potentialexplanationsincludesmall
samplesize; strongplaceboeffect, especiallywith intramus-
cular delivery of TT; heterogeneous speed of response to
TT in patients with PD; and short duration of follow-up.
The continued improvement in the St Louis Testosterone
Deficiency Scale scores in subjects in theTTgroupduring
the long-term,open-labelphasesuggestsadelay inresponse
in at least some patients with PD. The self-selected group
in the open-label phase may have exhibited a strong pla-
ceboeffectbecauseof theirawareness that theywerereceiv-
ing active treatment. Thus, future testosterone studies in
thispopulationmightbenefit froma longerdurationofob-
servation.On the other hand, analysis of the subjectswho
wereoriginallyrandomizedtoreceiveplacebowholaterchose
to receive TT in the open-label phase showed immediate
and sustained improvement in the St Louis Testosterone
Deficiency Scale, which suggests heterogeneity in the ra-
pidity of response to TT in this population.
Another potential explanation for these findings is the
recent and significant pathologic changes seen in post-
mortemhypothalamic analysis of brains frompatientswith
PD.34-39 These pathologic changes may affect both dis-
ease symptoms and potential treatments such as TT; how-
ever, the relationship between pathologic findings, symp-
toms, and response to therapy remains to be investigated.
The diagnosis of hypogonadism in older men is con-
troversial and could have affected the results of this study.
The American Association of Clinical Endocrinologists
defines definite testosterone deficiency as an earlymorn-
ing serum total testosterone level less than 200 ng/mL
(!6.9 mmol/L) with symptoms typical of hypogonad-
ism (eg, loss of libido, erectile dysfunction, and loss of
energy).40 The standard accepted by theUSFood andDrug
Administration for the administration of TT is a serum
total testosterone concentration less than 300 ng/dL (10.4
mmol/L).41 The patients in the TT arm of our study had
a baseline mean serum total testosterone concentration
of 375 ng/dL (13.0 mmol/L). Thus, patients in our TT
group had borderline hypogonadism. Bioavailable tes-
tosterone is the most accurate measurement,42 and fu-
ture studies of testosterone in PD should consider using
a bioavailable marker and selecting subjects with testos-
terone levels clearly in the deficient range.
Testosterone levels decline with normal aging, even
in healthymen.43 Cross-sectional and longitudinal stud-
ies have confirmed this decline, although the rate of de-
cline can differ among individuals.43-50 Twenty percent
or more of elderly men will experience a decline in tes-
tosterone level to the extent that symptoms of testoster-
one deficiency develop thatmay include frontal lobe dys-
function, memory impairment, depressed mood, and
fatigue or apathy.43,49 The Rancho-Bernardo Study51 was
performed using a cross-sectional design and examined
age-associated variations in total and bioavailable testos-
terone. Samples from 810 men aged 24 to 90 years were
examined for testosterone deficiency. Bioavailable tes-
tosterone decreased significantly with age, independent
of covariates.52 In a longitudinal analysis, Harman et al43
examined testosterone levels in 890 men in the Balti-
more Longitudinal Study on Aging. Independent, age-
invariant, longitudinal effects of age on testosterone level
were found. Several studies have shown improvements












































Figure 2. Open-label follow-up phase of patients after the 8-week study
(completed at visit 5) shows that patients who continued to receive
testosterone therapy (TT) (n=6) continued to demonstrate a downward trend
at the 3- and 6-month data points. The graph displays the change from











































Figure 3. After visit 5 (8-week study completion point), both the testosterone
therapy (TT) group (n=6) and the group who switched to testosterone
therapy during an open-label phase (n=3) showed improvement in St Louis
Testosterone Deficiency Questionnaire scores.
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placebo-controlled studies in patients older than 65 years,
TT failed to show significant improvements inmood, cog-
nition, or sexual function.53 Age may also have affected
the results of our study.
Other limitations of this study include the following:
other scales were underpowered to detect changes on
scales other than the St Louis Testosterone Deficiency
Scale; the stage of disease was not considered carefully
in the inclusion criteria; testosterone interactionwith do-
paminergic medications was not considered; and 2 av-
eraged free testosterone levels were used rather than a
bioavailable level.
Future directions for the study of testosterone defi-
ciency in PD will need to include investigations of epi-
demiology, the role of hormones in neurodegeneration,
and the effects of pathologic findings and hypothalamic
function in PD on testosterone. The results of this study
can be used in construction of a larger placebo-
controlled study of TT in PD. This potential study should
have a longer follow-up period to avoid placebo effects
and should use bioavailable testosterone levels, which are
a more reliable blood marker for testosterone defi-
ciency. Testosterone therapy should not be routinely ad-
ministered in patients with PD with symptoms of prob-
able testosterone deficiency. Suspicion of testosterone
deficiency in this population should be followed up by
obtaining a bioavailable testosterone level and referring
the patient to a medical expert for an examination and
discussion of the substantial risks of TT.
Accepted for Publication: December 15, 2005.
Author Affiliations: Departments of Neurology
(Drs Okun, Fernandez, Rodriguez, Foster, Shenal, and
Crucian, Messrs Armaghani and Jacobson, and Mss
Romrell, Suelter, andMunson),Neurosurgery (DrOkun),
and Psychiatry (Dr Okun), University of Florida Move-
mentDisorders Center,McKnight Brain Institute, Gaines-
ville; Gertude H. Sergievsky Center, College of Physi-
cians and Surgeons, ColumbiaUniversityMedical Center,
New York, NY (Drs Okun and Louis); Departments of
Medicine and Geriatrics, Geriatric Research, Education,
and Clinical Center, Malcolm Randall Veterans Affairs
Hospital andUniversity of Florida (DrMulligan); andDi-
vision of Biostatistics, College of Medicine, University of
Florida (Dr Wu).
Correspondence:Michael S. Okun, MD, Department of
Neurology, University of Florida Movement Disorders
Center,McKnight Brain Institute, POBox100236,Gaines-
ville, FL 32610 (okun@neurology.ufl.edu).
Author Contributions: Study concept and design: Okun,
Fernandez, Jacobson, and Crucian. Acquisition of data:
Okun, Fernandez, Jacobson, Rodriguez, Romrell, Suel-
ter,Munson, andFoster.Analysis and interpretation of data:
Okun, Fernandez, Louis, Mulligan, Armaghani,Wu, and
Crucian.Drafting of the manuscript:Okun, Fernandez, Ja-
cobson, and Rodriguez. Critical revision of the manu-
script for important intellectual content: Okun, Fernan-
dez, Jacobson and Romrell, Suelter, Munson, Louis,
Mulligan, Foster, Shenal, Armaghani, Wu, and Crucian.
Statistical analysis: Okun, Fernandez, Jacobson, Louis,
Mulligan,Wu, and Crucian.Obtained funding:Okun and
Crucian. Administrative, technical, and material support:
Okun, Rodriguez, Romrell, Suelter, Munson, Mulligan,
Shenal, and Armaghani. Study supervision: Okun,
Fernandez, Jacobson, and Munson.
Funding/Support: This study was supported by a grant
from the Michael J. Fox Foundation.
Acknowledgment:We thank Caroline Tanner, MD, and
Todd Sherer, PhD, for helpful comments on the data con-
tained in themanuscript, and JanineMilke, PhD, Robert
Rhodes, PhD, Cami Swartz, BS, Elizabeth Barton, Sandi
Bridges, Christina Sheehy, BS, Karen Schaudt, John Ford,
Scott Kahler, Lisa Singleton, and Karen Harbst-Citta,
ARNP, for assistance in coordinating important aspects
of this study.
REFERENCES
1. Harman SM, Tsitouras P. Reproductive hormones in aging men, I: measure-
ment of sex steroids, basal luteinizing hormone, and Leydig cell response to hu-
man chorionic gonadotropin. J Clin Endocrinol Metab. 1980;51:35-41.
2. Okun MS, DeLong MR, Hanfelt J, Gearing M, Levey A. Plasma testosterone lev-
els in Alzheimer and Parkinson diseases. Neurology. 2004;62:411-413.
3. OkunMS, McDonaldWM, DeLongMR. Refractory nonmotor symptoms in male
patients with Parkinson disease due to testosterone deficiency: a common un-
recognized comorbidity. Arch Neurol. 2002;59:807-811.
4. Hogervorst E, BandelowS, CombrinckM, Smith AD. Low free testosterone is an in-
dependent risk factor for Alzheimer’s disease. Exp Gerontol. 2004;39:1633-1639.
5. MarkianosM, PanasM, Kalfakis N, Vassilopoulos D. Plasma testosterone inmale
patients with Huntington’s disease: relations to severity of illness and dementia.
Ann Neurol. 2005;57:520-525.
6. Nutt JG, Wooten GF. Clinical practice. Diagnosis and initial management of Par-
kinson’s disease. N Engl J Med. 2005;353:1021-1027.
7. Lang AE, Obeso JA. Challenges in Parkinson’s disease: restoration of the nigro-
striatal dopamine system is not enough. Lancet Neurol. 2004;3:309-316.
8. Okun MS, Walter BL, McDonald WM, et al. Beneficial effects of testosterone re-
placement for the nonmotor symptoms of Parkinson disease.Arch Neurol. 2002;
59:1750-1753.
9. Morley JE, Charlton E, Patrick P, et al. Validation of a screening questionnaire
for androgen deficiency in aging males. Metabolism. 2000;49:1239-1242.
10. Smith KW, Feldman HA, McKinlay JB. Construction and field validation of a self-
administered screener for testosterone deficiency (hypogonadism) in ageingmen.
Clin Endocrinol (Oxf ). 2000;53:703-711.
11. Zenzola A, Masi G, De Mari M, Defazio G, Livrea P, Lamberti P. Fatigue in Par-
kinson’s disease. Neurol Sci. 2003;24:225-226.
12. Bergner M, Bobbitt RA, Pollard WE, Martin DP, Gilson BS. The Sickness Impact
Profile: validation of a health status measure. Med Care. 1976;14:57-67.
13. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson’s Dis-
ease Questionnaire (PDQ-39): development and validation of a Parkinson’s dis-
ease summary index score. Age Ageing. 1997;26:353-357.
14. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric de-
pression screening scale: a preliminary report. J Psychiatr Res. 1982;17:37-49.
15. Vedana L, Baiardi P, Sommaruga M, et al. Clinical validation of an anxiety and
depression screening test for intensive in-hospital rehabilitation. Monaldi Arch
Chest Dis. 2002;58:101-106.
16. Stern RA. Assessment of mood states in neurodegenerative disease: method-
ological issues and diagnostic recommendations. Semin Clin Neuropsychiatry.
1996;1:315-324.
17. Martinez-Martin P, Gil-Nagel A, Gracia LM, Gomez JB, Martinez-Sarries J, Ber-
mejo F; the Cooperative Multicentric Group. Unified Parkinson’s Disease Rating
Scale characteristics and structure. Mov Disord. 1994;9:76-83.
18. LezakMD, Howieson DB, Loring DW.Neuropsychological Assessment.NewYork,
NY: Oxford University Press; 2004.
19. Tinklenberg J, Brooks JO III, Tanke ED, et al. Factor analysis and preliminary vali-
dation of the Mini-Mental State Examination from a longitudinal perspective. Int
Psychogeriatr. 1990;2:123-134.
20. Eslinger PJ, Damasio AR, Benton AL, Van Allen M. Neuropsychologic detection
of abnormal mental decline in older persons. JAMA. 1985;253:670-674.
21. Amolsch TJ, Henrichs TF. Behavioral correlates of WAIS profile patterns: an ex-
ploratory study. J Pers Assess. 1975;39:55-63.
22. Howard AR. Further validation studies of the Wechsler Memory Scale. J Clin
Psychol. 1954;10:164-167.
23. Leli DA, Filskov SB. Actuarial assessment of Wechsler Verbal-Performance Scale
(REPRINTED) ARCH NEUROL /VOL 63, MAY 2006 WWW.ARCHNEUROL.COM
734
©2006 American Medical Association. All rights reserved.
differences as signs of lateralized cerebral impairment.Percept Mot Skills. 1981;
53:491-496.
24. Wechsler D. Wechsler Memory Scale, Manual. 3rd ed. San Antonio, Tex: Psy-
chological Corp; 1997.
25. Petrides M. Frontal lobes and behavior. Curr Opin Neurobiol. 1994;4:207-211.
26. PetridesM. Impairments on nonspatial self-ordered and externally ordered work-
ing memory tasks after lesions of the mid-dorsal part of the lateral frontal cortex
in the monkey. J Neurosci. 1995;15:359-375.
27. Petrides M, Pandya DN. Dorsolateral prefrontal cortex: comparative cytoarchi-
tectonic analysis in the human and the macaque brain and corticocortical con-
nection patterns. Eur J Neurosci. 1999;11:1011-1036.
28. Spreen O, Strauss E. A Compendium of Neuropsychological Tests. 2nd ed. New
York, NY: Oxford University Press; 1998.
29. Rubino IA, Fedeli B, Zanna V, Fortuna E. A multivariate study of the Serial Color-
Word Test. Percept Mot Skills. 1997;84:275-282.
30. Hogervorst E, Combrinck M, Lapuerta P, Rue J, Swales K, Budge M. The Hop-
kins Verbal Learning Test and screening for dementia.Dement Geriatr CognDisord.
2002;13:13-20.
31. Tenover JL. Experience with testosterone replacement in the elderly. Mayo Clin
Proc. 2000;75(suppl):S77-S82.
32. Tenover JS. Prevalence and management of mild hypogonadism: introduction.
Int J Impot Res. 2003;15(suppl 4):S1-S2.
33. Tenover JL. Testosterone replacement therapy in older adult men. Int J Androl.
1999;22:300-306.
34. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the devel-
opment of Parkinson’s disease-related pathology. Cell Tissue Res. 2004;318:
121-134.
35. Braak H, Braak E. Pathoanatomy of Parkinson’s disease.J Neurol. 2000;247(suppl
2):II3-II10.
36. Wakabayashi K, Takahashi H. Neuropathology of autonomic nervous system in
Parkinson’s disease. Eur Neurol. 1997;38(suppl 2):2-7.
37. Nakamura S, Ohnishi K, Nishimura M, et al. Large neurons in the tuberomam-
millary nucleus in patients with Parkinson’s disease andmultiple system atrophy.
Neurology. 1996;46:1693-1696.
38. Kremer HP, Bots GT. Lewy bodies in the lateral hypothalamus: do they imply neu-
ronal loss? Mov Disord. 1993;8:315-320.
39. KremerHP. The hypothalamic lateral tuberal nucleus: normal anatomy and changes
in neurological diseases. Prog Brain Res. 1992;93:249-261.
40. American Association of Clinical Endocrinologists. American Association of Clini-
cal Endocrinologists Medical Guidelines for clinical practice for the evaluation
and treatment of hypogonadism in adultmale patients–2002 update.Endocr Pract.
2002;8:440-456.
41. Hanna KE. No fountain of youth: FDA and NIH review off-label use of hormones.
Hastings Cent Rep. 2003;33:8-9.
42. Morley JE, Patrick P, Perry HM III. Evaluation of assays available to measure free
testosterone. Metabolism. 2002;51:554-559.
43. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR; Baltimore Longi-
tudinal Study of Aging. Longitudinal effects of aging on serum total and free tes-
tosterone levels in healthy men. J Clin Endocrinol Metab. 2001;86:724-731.
44. Gray A, Berlin JA, McKinlay JB, Longcope C. An examination of research design
effects on the association of testosterone and male ageing: results of a
meta-analysis. J Clin Epidemiol. 1991;44:671-684.
45. Vermeulen A. Clinical review 24: androgens in the aging male. J Clin Endocrinol
Metab. 1991;73:221-224.
46. Vermeulen A. Environment, human reproduction, menopause, and andropause.
Environ Health Perspect. 1993;101(suppl 2):91-100.
47. Vermeulen A, Kaufman JM. Ageing of the hypothalamo-pituitary-testicular axis
in men. Horm Res. 1995;43:25-28.
48. Tal S, Berner Y, Levy S. Influence of estrogen replacement therapy on cognitive
function and dementia in postmenopausal women [in Hebrew]. Harefuah. 1999;
137:636-639.
49. Tenover JS, Matsumoto AM, Plymate SR, Bremner WJ. The effects of aging in
normal men on bioavailable testosterone and luteinizing hormone secretion: re-
sponse to clomiphene citrate. J Clin Endocrinol Metab. 1987;65:1118-1126.
50. Tenover JS, Bremner WJ. The effects of normal aging on the response of the
pituitary-gonadal axis to chronic clomiphene administration in men. J Androl.
1991;12:258-263.
51. Barrett-Connor E, Von Muhlen DG, Kritz-Silverstein D. Bioavailable testosterone
and depressed mood in older men: the Rancho Bernardo Study. J Clin Endocri-
nol Metab. 1999;84:573-577.
52. Ferrini RL, Barrett-Connor E. Sex hormones and age: a cross-sectional study of
testosterone and estradiol and their bioavailable fractions in community-
dwelling men. Am J Epidemiol. 1998;147:750-754.
53. KrauseW, Mueller U, Mazur A. Testosterone supplementation in the aging male:
which questions have been answered? Aging Male. 2005;8:31-38.
Call for Papers
ARCHIVES Express
The ARCHIVES launched a new ARCHIVES Express section
in the September 2000 issue. This section will enable the
editors to publish highly selected papers within approxi-
mately 2 months of acceptance. We will consider only
themost significant research, the top 1% of accepted pa-
pers, on new important insights into the pathogenesis
of disease, brain function, and therapy. We encourage
authors to send their most exceptional clinical or basic
research, designating in the cover letter a request for ex-
peditedARCHIVES Express review.We look forward to pub-
lishing your important new research in this accelerated
manner.
Roger N. Rosenberg, MD
(REPRINTED) ARCH NEUROL /VOL 63, MAY 2006 WWW.ARCHNEUROL.COM
735
©2006 American Medical Association. All rights reserved.
